Drug Combination Details
| General Information of the Combination (ID: C74164) | |||||
|---|---|---|---|---|---|
| Name | Metformin NP Info | + | Olaparib Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Ovarian cancer
[ICD-11: 2C73]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | PARP1 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | UWB1.289 | CVCL_B079 | BRCA1 syndrome | Homo sapiens | ||
| UWB1.289+BRCA1 | CVCL_B078 | BRCA1 syndrome | Homo sapiens | |||
| SK-OV-3 | CVCL_0532 | Ovarian serous cystadenocarcinoma | Homo sapiens | |||
| OVCAR-3 | CVCL_0465 | Ovarian serous adenocarcinoma | Homo sapiens | |||
| A2780 | CVCL_0134 | Ovarian endometrioid adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Combining PARP inhibitors with metformin enhances its anti-proliferative activity in BRCA mutant ovarian cancer cells. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer. Gynecol Oncol. 2016 Aug;142(2):323-31. | |||
